Bringing the Oncology Community Together
Chronic Kidney Disease Associated With Increased Risk of Renal and Urothelial Cancers
Does renal disease increase one’s risk of developing cancer?
Read More >>
Targeting Src Adds No Benefit in VEGF-Resistant Metastatic Renal Cell Carcinoma
Durable Responses Observed with Nivolumab in Previously Treated mRCC
Not Yet Ready for Prime Time: Lessons Learned From a Failed Molecular Marker–Based Lung Cancer Trial
Genes That Drive Clear-Cell RCC Discovered, Providing Research Clues
In 2 Cancers, Robotic Versus Open Surgery is Explored
Regional Cancer Care Associates Delivers Value-Based Care
View More >>
- A Network of Your Peers
View more >>
PD-1 Inhibition in Renal Cell Carcinoma
Checkpoint Inhibition in Renal Cell Carcinoma
Nivolumab in Renal Cell Carcinoma
Most Popular Right Now
Tweets by @OncLive
Minimizing Toxicity While Maintaining Efficacy in RCC
Moderated by Robert A. Figlin, MD, this panel discussion includes expert perspectives from Daniel J. George, MD, Sumanta Kumar Pal, MD, Brian I. Rini, MD, and Nizar M. Tannir, MD.
Avastin (bevacizumab) Plus IFN in mRCC
Ronald Bukowski, MD, and Thomas Hutson, DO, PharmD, disucss bevacizumab in metastatic renal cell carcinoma.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
666 Plainsboro Road
Plainsboro, NJ 08536
Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.